ATE445006T1 - Differenzierung von nicht-insulin in insulin- produzierende zellen durch glp-1 und exendin-4 und dessen verwendung - Google Patents

Differenzierung von nicht-insulin in insulin- produzierende zellen durch glp-1 und exendin-4 und dessen verwendung

Info

Publication number: ATE445006T1
Authority: AT; Austria
Prior art keywords: insulin; producing cells; exendin; glp; differentiation
Prior art date: 1998-08-10

Application number

AT99942066T

Other languages

English (en)

Inventor

Josephine Egan

Riccardo Perfetti

Antonino Passaniti

Nigel Greig

Harold Holloway

Original Assignee

Us Gov Health & Human Serv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-10

Filing date

1999-08-10

Publication date

2009-10-15

1999-08-10 Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv

2009-10-15 Application granted granted Critical

2009-10-15 Publication of ATE445006T1 publication Critical patent/ATE445006T1/de

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Substances N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 11
229940125396 insulin Drugs 0.000 title abstract 6
108010011459 Exenatide Proteins 0.000 title abstract 3
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 title abstract 3
102100025101 GATA-type zinc finger protein 1 Human genes 0.000 title abstract 3
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 3
229960001519 exenatide Drugs 0.000 title abstract 3
HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 title 1
230000004069 differentiation Effects 0.000 title 1
102000004877 Insulin Human genes 0.000 abstract 5
108090001061 Insulin Proteins 0.000 abstract 5
JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 abstract 2
239000003102 growth factor Substances 0.000 abstract 2
150000001413 amino acids Chemical group 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/335—Glucagon; Glucagon-like peptide [GLP]; Exendin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Endocrinology (AREA)
Cell Biology (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Epidemiology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Wood Science & Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Developmental Biology & Embryology (AREA)
Nutrition Science (AREA)
Virology (AREA)
Biophysics (AREA)
Toxicology (AREA)
Vascular Medicine (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Physiology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)

AT99942066T 1998-08-10 1999-08-10 Differenzierung von nicht-insulin in insulin- produzierende zellen durch glp-1 und exendin-4 und dessen verwendung ATE445006T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US9591798P	1998-08-10	1998-08-10
PCT/US1999/018099 WO2000009666A2 (en)	1998-08-10	1999-08-10	Differentiation of non-insulin producing cells into insulin producing cells by glp-1 or exendin-4 and uses thereof

Publications (1)

Publication Number	Publication Date
ATE445006T1 true ATE445006T1 (de)	2009-10-15

Family

ID=22254191

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99942066T ATE445006T1 (de)	1998-08-10	1999-08-10	Differenzierung von nicht-insulin in insulin- produzierende zellen durch glp-1 und exendin-4 und dessen verwendung

Country Status (10)

Country	Link
US (2)	US7056734B1 (de)
EP (2)	EP2028269B1 (de)
JP (4)	JP4624558B2 (de)
AT (1)	ATE445006T1 (de)
AU (1)	AU776514B2 (de)
CA (1)	CA2339326A1 (de)
DE (1)	DE69941510D1 (de)
DK (1)	DK1105460T3 (de)
ES (2)	ES2335066T3 (de)
WO (1)	WO2000009666A2 (de)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7138486B2 (en) *	1986-05-05	2006-11-21	The General Hospital Corporation	Insulinotropic hormone derivatives and uses thereof
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6703017B1 (en)	1994-04-28	2004-03-09	Ixion Biotechnology, Inc.	Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures
US6699973B1 (en) *	1998-11-19	2004-03-02	Elan Corporation, Plc	Antibodies to peptides that target GIT receptors and related methods
US6242666B1 (en) *	1998-12-16	2001-06-05	The Scripps Research Institute	Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells
US6967019B2 (en) *	1999-04-06	2005-11-22	The Regents Of The University Of California	Production of pancreatic islet cells and delivery of insulin
US6528486B1 (en)	1999-07-12	2003-03-04	Zealand Pharma A/S	Peptide agonists of GLP-1 activity
US20030082155A1 (en) *	1999-12-06	2003-05-01	Habener Joel F.	Stem cells of the islets of langerhans and their use in treating diabetes mellitus
US6448045B1 (en) *	2000-03-10	2002-09-10	The Regents Of The University Of California	Inducing insulin gene expression in pancreas cells expressing recombinant PDX-1
EP2213743A1 (de)	2000-04-12	2010-08-04	Human Genome Sciences, Inc.	Albuminfusionsproteine
CA2430934C (en)	2000-12-01	2011-06-21	Takeda Chemical Industries, Ltd.	A method of producing sustained-release preparations of a bioactive substance using high-pressure gas
ATE408414T1 (de)	2001-07-31	2008-10-15	Us Gov Health & Human Serv	Glp 1 exendin 4 peptidanaloga und deren verwendungen
US6642003B2 (en)	2001-08-02	2003-11-04	Cedars-Sinai Medical Center	Human glucose-dependent insulin-secreting cell line
US6911324B2 (en)	2001-10-18	2005-06-28	The Regents Of The University Of California	Induction of beta cell differentiation in human cells
KR20090115984A (ko) *	2001-11-09	2009-11-10	아르테셀 사이언스, 인크.	지방 조직에서 유래된 기질세포의 내분비 췌장 분화 및 이의 용도
AU2002364586A1 (en)	2001-12-21	2003-07-30	Delta Biotechnology Limited	Albumin fusion proteins
WO2005003296A2 (en)	2003-01-22	2005-01-13	Human Genome Sciences, Inc.	Albumin fusion proteins
DE60335608D1 (de) *	2002-02-27	2011-02-17	Pharmain Corp	Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung
US7635463B2 (en)	2002-02-27	2009-12-22	Pharmain Corporation	Compositions for delivery of therapeutics and other materials
WO2003102171A1 (en) *	2002-05-28	2003-12-11	Becton, Dickinson And Company	Expansion and transdifferentiation of human acinar cells
JP2006503080A (ja)	2002-10-11	2006-01-26	ノボセルインコーポレイテッド	疾患治療用のカプセルで包んだ生物材料の移植
EP1688148A1 (de) *	2002-12-03	2006-08-09	Novo Nordisk A/S	Behandlung mit Kombinationspräparaten aus Exendin-4 und Thiazolidindionen
WO2004050115A2 (en) *	2002-12-03	2004-06-17	Novo Nordisk A/S	Combination treatment using exendin-4 and thiazolidinediones
DE602004031927D1 (de)	2003-02-04	2011-05-05	Novo Nordisk As	Injektionsvorrichtung mit drehbarer dosiseinstellungsvorrichtung
CA2518465A1 (en)	2003-03-25	2004-10-14	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
DK1636348T3 (da) *	2003-06-20	2009-11-23	Vrije Universiteit Brussel Vub	Fremgangsmåde til generering af beta-öceller ud fra eksokrine pankreatiske celler
US8790637B2 (en)	2003-06-27	2014-07-29	DePuy Synthes Products, LLC	Repair and regeneration of ocular tissue using postpartum-derived cells
US9572840B2 (en)	2003-06-27	2017-02-21	DePuy Synthes Products, Inc.	Regeneration and repair of neural tissue using postpartum-derived cells
WO2005001080A2 (en)	2003-06-27	2005-01-06	Ethicon, Incorporated	Postpartum-derived cells for use in treatment of disease of the heart and circulatory system
US9592258B2 (en)	2003-06-27	2017-03-14	DePuy Synthes Products, Inc.	Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
KR20060041309A (ko)	2003-08-13	2006-05-11	다케다 야쿠힌 고교 가부시키가이샤	４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
BRPI0506662B8 (pt)	2004-01-06	2021-05-25	Novo Nordisk As	compostos ativadores de glucoquinase
ES2642214T3 (es)	2004-01-21	2017-11-15	Novo Nordisk Health Care Ag	Conjugación de péptidos mediante transglutaminasa
WO2005112977A2 (en) *	2004-04-23	2005-12-01	Pharmain, Ltd.	Compositions for treatment with glucagon-like peptide, and methods of making and using the same
EP1767618A4 (de) *	2004-06-03	2008-07-30	Univ Kyoto	Induktion einer insulin sezernierenden zelle
EP1824835A1 (de)	2004-12-03	2007-08-29	Novo Nordisk A/S	Heteroaromatische glucokinaseaktivatoren
EP1904467B1 (de)	2005-07-14	2013-05-01	Novo Nordisk A/S	Harnstoff-Glucokinase-Aktivatoren
MY147393A (en)	2005-09-14	2012-11-30	Takeda Pharmaceutical	Administration of dipeptidyl peptidase inhibitors
CA2622642C (en)	2005-09-16	2013-12-31	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
WO2007070870A1 (en)	2005-12-16	2007-06-21	Ethicon, Inc.	Compositions and methods for inhibiting adverse immune response in histocompatibility-mismatched transplantation
KR101529318B1 (ko)	2005-12-19	2015-06-16	파마인 코포레이션	치료제를 전달하기 위한 소수성 코어 담체 조성물, 이조성물의 제조 방법 및 그 조성물의 이용 방법
US9125906B2 (en)	2005-12-28	2015-09-08	DePuy Synthes Products, Inc.	Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
EP1996224B1 (de)	2006-03-15	2012-11-07	Novo Nordisk A/S	Mischungen aus amylin und insulin
US8324383B2 (en)	2006-09-13	2012-12-04	Takeda Pharmaceutical Company Limited	Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en)	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
JP5226008B2 (ja)	2007-01-11	2013-07-03	ノボ・ノルデイスク・エー／エス	ウレアグルコキナーゼアクチベーター
RU2413528C2 (ru)	2007-01-18	2011-03-10	Открытое Акционерное Общество "Валента Фармацевтика"	Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
US8093236B2 (en)	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
JP5688969B2 (ja)	2007-07-16	2015-03-25	ノボ・ノルデイスク・エー／エス	プロテアーゼに対して安定しているペグ化インスリンアナログ
US7960336B2 (en) *	2007-08-03	2011-06-14	Pharmain Corporation	Composition for long-acting peptide analogs
US8563527B2 (en) *	2007-08-20	2013-10-22	Pharmain Corporation	Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090176892A1 (en)	2008-01-09	2009-07-09	Pharmain Corporation	Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
US20110046071A1 (en) *	2008-03-05	2011-02-24	Tel Hashomer Medical Research Infrastructure And Services Ltd.	GLP-1 Receptor Agonists And Related Active Pharmaceutical Ingredients For Treatment Of Cancer
HUE032284T2 (en)	2008-03-18	2017-09-28	Novo Nordisk As	Protease-stabilized, acylated insulin analogues
CN102131516B (zh)	2008-06-27	2016-03-16	杜克大学	包含弹性蛋白样肽的治疗剂
CN102387807A (zh)	2008-12-19	2012-03-21	先进科技及再生医学有限责任公司	肺部疾病和病症的治疗
US10179900B2 (en)	2008-12-19	2019-01-15	DePuy Synthes Products, Inc.	Conditioned media and methods of making a conditioned media
SG174551A1 (en)	2009-03-26	2011-10-28	Ethicon Inc	Human umbilical cord tissue cells as therapy for alzheimer' s disease
CN101991580B (zh) *	2009-08-28	2013-03-20	杏辉天力（杭州）药业有限公司	以羊毛甾烷及茯苓萃取物治疗糖尿病的用途
WO2011064316A2 (en)	2009-11-25	2011-06-03	Paolo Botti	Mucosal delivery of peptides
CN107129538B (zh)	2010-04-27	2021-07-16	西兰制药公司	Glp-1受体激动剂和胃泌素的肽缀合物及其用途
CN103429739B (zh)	2010-05-12	2018-11-13	哥伦比亚大学纽约管理委员会	制备产生和分泌胰岛素的肠内分泌细胞的方法
TW201326194A (zh)	2011-11-03	2013-07-01	Zealand Pharma As	Ｇｌｐ－１胃泌素受體促效劑肽結合物
AU2012358810B2 (en)	2011-12-23	2018-03-15	DePuy Synthes Products, Inc.	Detection of human umbilical cord tissue-derived cells
IN2015DN00544A (de)	2012-07-23	2015-06-26	Zealand Pharma As
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
AU2013366692B2 (en)	2012-12-21	2017-11-23	Sanofi	Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
PL3057984T3 (pl)	2013-10-17	2018-12-31	Zealand Pharma A/S	Acylowane analogi glukagonu
CN105829339B (zh)	2013-11-06	2021-03-12	西兰制药公司	胰高血糖素-glp-1-gip三重激动剂化合物
WO2015067715A2 (en)	2013-11-06	2015-05-14	Zealand Pharma A/S	Gip-glp-1 dual agonist compounds and methods
EP3080152A1 (de)	2013-12-13	2016-10-19	Sanofi	Nicht-acylierte exendin-4-peptidanaloga
EP3080154B1 (de)	2013-12-13	2018-02-07	Sanofi	Duale glp-1/gip-rezeptoragonisten
WO2015086733A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/glucagon receptor agonists
WO2015086728A1 (en)	2013-12-13	2015-06-18	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
JP2017513875A (ja) *	2014-04-22	2017-06-01	ティーエックスピーファーマゲゼルシャフトミットベシュレンクテルハフツング	分枝状アミノ酸プローブを有するペプチド類似体
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
US10487314B2 (en)	2014-06-26	2019-11-26	The Trustees Of Columbia University In The City Of New York	Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
RU2573933C1 (ru)	2014-08-21	2016-01-27	Дафот Энтерпрайсис Лимитед	Пептид для лечения сахарного диабета 2-го типа и его осложнений
KR102620911B1 (ko)	2014-10-29	2024-01-05	질랜드 파마 에이/에스	Gip 효능제 화합물 및 방법
DK3283507T3 (da)	2015-04-16	2020-01-02	Zealand Pharma As	Acyleret glucagonanalog
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
EP3551651B1 (de)	2016-12-09	2024-03-06	Zealand Pharma A/S	Acylierte glp-1/glp-2 duale agoniste
CN109679964A (zh) *	2019-01-12	2019-04-26	青岛华义宏博生物科技有限公司	一种表达人胰岛素基因的重组乳酸乳球菌
EP3938037A1 (de)	2019-03-15	2022-01-19	Diet4Life ApS	Kombination von diätetischen peptiden

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5614492A (en)	1986-05-05	1997-03-25	The General Hospital Corporation	Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5545618A (en)	1990-01-24	1996-08-13	Buckley; Douglas I.	GLP-1 analogs useful for diabetes treatment
AU4114493A (en) *	1992-04-24	1993-11-29	Polymer Technology Group, Inc., The	Method of culturing viable cells and method of regulating the level of a compound in a body fluid
EP0969016A2 (de)	1992-06-15	2000-01-05	Scios Inc.	Dem Glukagon ähnliche Peptide und Insulinotropin-Derivate
HU225496B1 (en)	1993-04-07	2007-01-29	Scios Inc	Pharmaceutical compositions of prolonged delivery, containing peptides
US5424286A (en) *	1993-05-24	1995-06-13	Eng; John	Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
CA2137206A1 (en)	1993-12-09	1995-06-10	John A. Galloway	Glucagon-like insulinotropic peptides, compositions and methods
GB9409496D0 (en)	1994-05-12	1994-06-29	London Health Ass	Method for improving glycaemic control in diabetes
ATE493998T1 (de) *	1996-08-08	2011-01-15	Amylin Pharmaceuticals Inc	Pharmazeutische zusammensetzung mit einem exendin-4-peptid
EP1056774A1 (de)	1998-02-27	2000-12-06	Novo Nordisk A/S	N-terminal verkürzte glp-1 derivate
ATE251465T1 (de)	1998-07-31	2003-10-15	Novo Nordisk As	In-vitro stimulation von beta zellen vermehrung

1999
- 1999-08-10 DE DE69941510T patent/DE69941510D1/de not_active Expired - Lifetime
- 1999-08-10 CA CA002339326A patent/CA2339326A1/en not_active Abandoned
- 1999-08-10 EP EP08019260.2A patent/EP2028269B1/de not_active Expired - Lifetime
- 1999-08-10 ES ES99942066T patent/ES2335066T3/es not_active Expired - Lifetime
- 1999-08-10 WO PCT/US1999/018099 patent/WO2000009666A2/en not_active Ceased
- 1999-08-10 DK DK99942066.4T patent/DK1105460T3/da active
- 1999-08-10 AT AT99942066T patent/ATE445006T1/de active
- 1999-08-10 EP EP99942066A patent/EP1105460B1/de not_active Expired - Lifetime
- 1999-08-10 US US09/762,538 patent/US7056734B1/en not_active Expired - Fee Related
- 1999-08-10 JP JP2000565103A patent/JP4624558B2/ja not_active Expired - Fee Related
- 1999-08-10 ES ES08019260.2T patent/ES2553108T3/es not_active Expired - Lifetime
- 1999-08-10 AU AU55524/99A patent/AU776514B2/en not_active Ceased
2006
- 2006-04-07 US US11/400,715 patent/US20070041951A1/en not_active Abandoned
2007
- 2007-04-24 JP JP2007114374A patent/JP4755133B2/ja not_active Expired - Fee Related
2009
- 2009-08-07 JP JP2009184807A patent/JP2009291206A/ja active Pending
2011
- 2011-04-05 JP JP2011083828A patent/JP2011177181A/ja active Pending

Also Published As

Publication number	Publication date
US20070041951A1 (en)	2007-02-22
JP2011177181A (ja)	2011-09-15
JP4755133B2 (ja)	2011-08-24
EP1105460A2 (de)	2001-06-13
WO2000009666A9 (en)	2000-07-13
AU5552499A (en)	2000-03-06
JP2002522068A (ja)	2002-07-23
JP4624558B2 (ja)	2011-02-02
WO2000009666A2 (en)	2000-02-24
ES2553108T3 (es)	2015-12-04
AU776514B2 (en)	2004-09-09
CA2339326A1 (en)	2000-02-24
DE69941510D1 (de)	2009-11-19
JP2007209348A (ja)	2007-08-23
DK1105460T3 (da)	2010-02-08
JP2009291206A (ja)	2009-12-17
ES2335066T3 (es)	2010-03-18
US7056734B1 (en)	2006-06-06
EP2028269A1 (de)	2009-02-25
WO2000009666A3 (en)	2000-11-23
EP2028269B1 (de)	2015-10-21
EP1105460B1 (de)	2009-10-07

Legal Events

Date

Code

Title

Description

2010-06-15

UEP

Publication of translation of european patent specification

Ref document number: 1105460

Country of ref document: EP

Publication	Publication Date	Title
ATE445006T1 (de)	2009-10-15	Differenzierung von nicht-insulin in insulin- produzierende zellen durch glp-1 und exendin-4 und dessen verwendung
DE69532914D1 (de)	2004-05-27	Glucagonähnliche, insulinotrope Komplexe, ihre Zusammensetzungen und ihr Herstellungsverfahren
TR199802252T2 (xx)	1999-02-22	N�ral ve renal geli�menin uyar�lmas� i�in ret ligand� (RetL)
DE69333112D1 (de)	2003-08-28	Modifizierte pilzzellen und methode zur herstelllung rekombinanter produkte
DE69225432D1 (de)	1998-06-18	A-C-B-Proinsulin, Verfahren zu seiner Herstellung und Verwendung, und Zwischenprodukte in der Insulin-Produktion
DE23193606T1 (de)	2024-02-15	Verfahren zur erhöhung der funktion eines aav-vektors
DE68926892D1 (de)	1996-09-05	Verfahren zur Herstellung von Zellen, die stabil integrierte fremde DNS mit hoher Kopiezahl enthalten, durch dieses Verfahren hergestellte Zellen und Verwendung dieser Zellen zur Herstellung von durch diese fremde DNS kodierten Polypeptiden
DE69620766D1 (de)	2002-05-23	Verfahren zur herstellung von polypeptidabkömmlingen
ATE251465T1 (de)	2003-10-15	In-vitro stimulation von beta zellen vermehrung
ATE138101T1 (de)	1996-06-15	Dna-fragment, das ein polypeptid mit nitrilhydrataseaktivität kodiert, dna-fragment enthaltende transformante und verfahren zur herstellung von amiden unter verwendung der transformante
PT955313E (pt)	2006-07-31	Nova proteina e processo para a sua producao
DE286239T1 (de)	1994-02-24	Herstellung und Reinigung eines Proteins, das mit einem Bindungsprotein fusioniert ist.
ATE401413T1 (de)	2008-08-15	Verfahren zur herstellung von l-aminosäuren, unter verwendung von stämmen aus der familie der enterobacteriaceae, welche ein attenuiertes acea- gen enthalten
WO2002074045A3 (en)	2003-03-20	Production of pancreatic islet cells and delivery of insulin
ATE502305T1 (de)	2011-04-15	Verwendung von vorstufen von enkephalinen und/oder deren fragmenten in der medizinischen diagnostik
DE03779067T1 (de)	2006-06-22	Fluoreszenzproteine und chromoproteine aus nicht-aequorea-hydrozoa-spezies sowie verfahren zur verwendung davon
EP0546074A4 (en)	1994-08-17	Genetic material encoding igfbp-5
ATE194167T1 (de)	2000-07-15	Ein prozess für die herstellung von faktor ix biologischen ursprungs
ATE384781T1 (de)	2008-02-15	Verfahren zur herstellung von entwickelten und unentwickelten pankreasendokrinezellen, zellpräparat und verwendung davon zur behandlung von diabetes
DE69728654D1 (de)	2004-05-19	Verwendung von il-7 zur behandlung von autoimmunkrankheiten, insbesondere insulinabhängigem diabetes mellitus
DE10214653A1 (de)	2003-03-27	Ein Verfahren zur Herstellung einer Gen-Bank mutierter Proteine mit unterschiedlichen Größen und unterschiedlichen Sequenzen
DE69734779D1 (de)	2006-01-05	Erhöhte ausbeuten eines kristallinen proteins durch verwendung eines festen adsorptionsmaterials
DE1929T1 (de)	1980-07-24	Synthetische DNA und Verfahren zu ihrer Herstellung
DE69733571D1 (de)	2005-07-21	Eine methode zur erhöhung der transfektion von zellen
EP0470520A2 (de)	1992-02-12	Verfahren zur Herstellung von Peptiden und Polypeptiden in einem zellfreien Translationssystem